Gender-specific symptom outcomes on cariprazine treatment: a 12-month naturalistic longitudinal follow-up study in schizophrenia - Report - MDSpire

Gender-specific symptom outcomes on cariprazine treatment: a 12-month naturalistic longitudinal follow-up study in schizophrenia

  • By

  • Claudia Carmassi

  • Virginia Pedrinelli

  • Andrea Bordacchini

  • Berenice Rimoldi

  • Livia Parrini

  • Carlo A. Bertelloni

  • Valerio Dell’Oste

  • June 23, 2026

  • 0 min

Share

Clinical Report: Gender-Differentiated Treatment Outcomes with Cariprazine

Overview

This study investigates the gender-specific treatment outcomes of cariprazine in schizophrenia over 12 months. Both men and women showed improvements in psychopathological symptoms.

Background

Understanding gender differences in treatment response is crucial for optimizing schizophrenia management. Previous research indicates that men and women may experience varying symptoms and treatment outcomes.

Data Highlights

GenderMean Dose (mg)PANSS Improvement
Men4.2 ± 1.3Improved in all subscales except uncontrolled hostility/excitement
Women4.0 ± 1.5Improved in all subscales

Key Findings

  • Both genders showed improvements in PANSS subscale symptoms after 6 and 12 months of treatment.
  • Men exhibited no improvement in the Uncontrolled hostility/excitement Marder factor.
  • Gender-specific response profiles emerged in PANSS subscales after 6 and 12 months.
  • The mean dose of cariprazine was similar between men (4.2 mg) and women (4.0 mg).

Clinical Implications

Clinicians should consider gender differences when evaluating treatment responses in schizophrenia.

Conclusion

Cariprazine demonstrates significant efficacy in treating schizophrenia in both men and women.

Related Resources & Content

  1. BMC Psychiatry, 2025 -- Unexpected Improvement of Clozapine-Related Obsessive-Compulsive Symptoms with Cariprazine Addition: A Case Study
  2. BMC Psychiatry, 2025 -- Changes in Subcortical Volume and Their Relationship with Social Functioning in Schizophrenia Patients Treated with Chlorpromazine Compared to Clozapine
  3. BMC Psychiatry, 2025 -- Assessing the metabolic impact of aripiprazole versus risperidone in the treatment of schizophrenia: a randomized double-blind controlled clinical trial
  4. Pharmacological and Somatic Treatments for First-Episode Psychosis and Schizophrenia: Synopsis of the US Department of Veterans Affairs and US Department of Defense Clinical Practice Guidelines
  5. July 2025 exceptional surveillance of psychosis and schizophrenia in adults: prevention and management (NICE guideline CG178)
  6. Drugs - Real World Outcomes — Monthly Long-Acting Injectable Aripiprazole for Schizophrenia Patients with Concurrent Substance Use Disorders: Findings from a Multicenter Observational Study
  7. Pharmacological and Somatic Treatments for First-Episode Psychosis and Schizophrenia: Synopsis of the US Department of Veterans Affairs and US Department of Defense Clinical Practice Guidelines
  8. July 2025 exceptional surveillance of psychosis and schizophrenia in adults: prevention and management (NICE guideline CG178)
  9. Die neue S3-Leitlinie Schizophrenie (living) 2025 | Der Nervenarzt | Springer Nature Link
  10. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial - ScienceDirect
  11. Lancet 2017, 389: 1103-13; 18 March 2017
  12. https://academic.oup.com/schizbullopen/advance-article/doi/10.1093/schizbullopen/sgaf024/8287580
  13. Antipsychotic dose and efficacy for acute schizophrenia spectrum disorders: an updated systematic review and dose-response meta-analysis - PMC
  14. Effects of cariprazine on cholesterol, glucose, and weight in patients with schizophrenia: a systematic review and meta-analysis
  15. Gender differences in the response to antipsychotic medication in patients with schizophrenia: An individual patient data meta-analysis of placebo-controlled studies - ScienceDirect
  16. Frontiers | Sex differences in schizophrenia: symptomatology, treatment efficacy and adverse effects
  17. Frontiers | Gender-stratified 9-month comparison of paliperidone extended-release tablets and paliperidone palmitate injection in schizophrenia
  18. Frontiers | A 12-month longitudinal naturalistic follow-up of cariprazine in schizophrenia

Original Source(s)

Gender-specific symptom outcomes on cariprazine treatment: a 12-month naturalistic longitudinal follow-up study in schizophrenia

  • by Claudia Carmassi, Virginia Pedrinelli, Andrea Bordacchini, Berenice Rimoldi, Livia Parrini, Carlo A. Bertelloni, Valerio Dell’Oste

  • June 23, 2026

Related Content

Stewardship Cuts Steroid Prescribing

Behaviorally informed peer comparison feedback was associated with a gradual decline in glucocorticoid prescribing

SAMHSA Awards $255 Million to Administer 988 Lifeline

From cats to cortex: T. gondii and psychosis, depression, and anxiety